On the public citation graph

Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors

https://doi.org/10.1007/s00280-015-2830-8
0 signed · 66 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.exphem.2013.11.012openalex-snapshot
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
inferredcites →https://doi.org/10.1016/s1470-2045(12)70474-6openalex-snapshot
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
inferredcites →https://doi.org/10.1021/ml4000657openalex-snapshot
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
inferredcites →https://doi.org/10.1038/nrc991openalex-snapshot
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
inferredcites →https://doi.org/10.1158/0008-5472.can-12-2807openalex-snapshot
MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-0460openalex-snapshot
Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
inferredcites →https://doi.org/10.1200/jco.2012.30.15_suppl.e13600openalex-snapshot
A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4003211openalex-extracted
Identification of ZER6 Isoform p52-ZER6 as an Antitumour Therapeutic Response Determinant for MDM2-p53 Binding Inhibitors
inferred← citeshttps://doi.org/10.1007/7355_2017_27openalex-snapshot
Protein–Protein Interaction Inhibitors
inferred← citeshttps://doi.org/10.1007/s00280-018-3521-zopenalex-snapshot
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors
inferred← citeshttps://doi.org/10.1007/s10238-026-02049-yopenalex-snapshot
Novel antagonist APG-115 targets MDM2-p53 to induce p53-mediated apoptosis and radiosensitization in colorectal cancer
inferred← citeshttps://doi.org/10.1007/s10495-022-01728-xopenalex-snapshot
p53 m6A modulation sensitizes hepatocellular carcinoma to apatinib through apoptosis
inferred← citeshttps://doi.org/10.1007/s11864-019-0622-9openalex-snapshot
The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma
inferred← citeshttps://doi.org/10.1007/s12282-026-01857-0openalex-snapshot
Targeting breast cancer senescence in 3D models of bone metastasis
inferred← citeshttps://doi.org/10.1016/j.apsb.2020.01.003openalex-snapshot
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
inferred← citeshttps://doi.org/10.1016/j.arr.2026.103218openalex-snapshot
Ubiquitination in cardiovascular diseases: From molecular mechanisms to therapeutic targeting
inferred← citeshttps://doi.org/10.1016/j.diagmicrobio.2022.115715openalex-snapshot
Clearing Chlamydia abortus infection in epithelial cells and primary human macrophages by use of antibiotics and the MDM2-p53-inhibitor nutlin-3
inferred← citeshttps://doi.org/10.1016/j.drudis.2013.08.012openalex-snapshot
Targeting the nucleolus for cancer-specific activation of p53
inferred← citeshttps://doi.org/10.1016/j.molmed.2013.07.005openalex-snapshot
The nucleolus: an emerging target for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2024.108742openalex-snapshot
Lessons learned from 20 years of preclinical testing in pediatric cancers
inferred← citeshttps://doi.org/10.1016/j.phrs.2020.105145openalex-snapshot
The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer
inferred← citeshttps://doi.org/10.1016/j.phrs.2026.108314openalex-snapshot
PET radiotracers targeting MDM2 protein interaction: From preclinical validation to first-in-human studies
inferred← citeshttps://doi.org/10.1021/acs.chemrev.3c00131openalex-snapshot
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.7b00498openalex-snapshot
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.9b01541openalex-snapshot
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
inferred← citeshttps://doi.org/10.1038/s41375-021-01446-4openalex-snapshot
Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells
inferred← citeshttps://doi.org/10.1038/s41375-026-02975-6openalex-snapshot
MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms
inferred← citeshttps://doi.org/10.1038/s41401-022-00973-9openalex-snapshot
p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors
inferred← citeshttps://doi.org/10.1038/s41401-024-01394-6openalex-snapshot
A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth
inferred← citeshttps://doi.org/10.1038/s41467-023-43039-yopenalex-snapshot
Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension
inferred← citeshttps://doi.org/10.1038/s41598-020-67510-8openalex-snapshot
Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction
inferred← citeshttps://doi.org/10.1042/bcj20240757openalex-snapshot
Structure and function of MDM2 and MDM4 in health and disease
inferred← citeshttps://doi.org/10.1051/e3sconf/202130802015openalex-snapshot
MDM2 inhibitors: Targeting p53-MDM2 interaction to anti-cancer
inferred← citeshttps://doi.org/10.1073/pnas.1703683114openalex-snapshot
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases
inferred← citeshttps://doi.org/10.1084/jem.20171066openalex-snapshot
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
inferred← citeshttps://doi.org/10.1093/narcan/zcad002openalex-snapshot
Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation
inferred← citeshttps://doi.org/10.1111/cas.14875openalex-snapshot
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
inferred← citeshttps://doi.org/10.1124/pharmrev.123.001026openalex-snapshot
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
inferred← citeshttps://doi.org/10.1186/s12917-023-03789-9openalex-snapshot
Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.1186/s12943-024-02046-3openalex-snapshot
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
inferred← citeshttps://doi.org/10.1186/s13045-017-0500-5openalex-snapshot
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
inferred← citeshttps://doi.org/10.1186/s13045-021-01169-0openalex-snapshot
Targeting mutant p53 for cancer therapy: direct and indirect strategies
inferred← citeshttps://doi.org/10.12677/acm.2023.1381881openalex-snapshot
Recent Advancements on the Anti-Tumor Small Molecule Inhibitors Targeting the p53-MDM2 Interaction
inferred← citeshttps://doi.org/10.1515/chem-2025-0142openalex-snapshot
Resveratrol-derived MDM2 inhibitors: Synthesis, characterization, and biological evaluation against MDM2 and HCT-116 cells
inferred← citeshttps://doi.org/10.1517/13543784.2014.892924openalex-snapshot
The clinical development of p53-reactivating drugs in sarcomas – charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins
inferred← citeshttps://doi.org/10.18632/oncotarget.9302openalex-snapshot
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
inferred← citeshttps://doi.org/10.2174/0118715206358340250121060830openalex-snapshot
Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction
inferred← citeshttps://doi.org/10.3389/fonc.2022.1006959openalex-snapshot
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
inferred← citeshttps://doi.org/10.3389/fphar.2020.00631openalex-snapshot
Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer
inferred← citeshttps://doi.org/10.3390/biom12040548openalex-snapshot
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
inferred← citeshttps://doi.org/10.3390/cancers13123079openalex-snapshot
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
inferred← citeshttps://doi.org/10.3390/cancers15174326openalex-snapshot
Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
inferred← citeshttps://doi.org/10.3390/cancers16101808openalex-snapshot
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
inferred← citeshttps://doi.org/10.3390/cells14080583openalex-snapshot
Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction
inferred← citeshttps://doi.org/10.3390/cells8091090openalex-snapshot
Therapeutic Approaches Targeting Nucleolus in Cancer
inferred← citeshttps://doi.org/10.3390/ijms24097842openalex-snapshot
Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches
inferred← citeshttps://doi.org/10.36401/jipo-20-4openalex-snapshot
Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results
inferred← citeshttps://doi.org/10.53846/goediss-7056openalex-snapshot
Targeting MDM2, the antagonist of the tumor suppressor p53
inferred← citeshttps://doi.org/10.6084/m9.figshare.24797875openalex-snapshot
Additional file 1 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.24798147openalex-snapshot
Additional file 2 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652987openalex-snapshot
Additional file 3 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652990openalex-snapshot
Additional file 4 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652993openalex-snapshot
Additional file 5 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652996openalex-snapshot
Additional file 6 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652999openalex-snapshot
Additional file 7 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
inferred← citeshttps://doi.org/10.6084/m9.figshare.26653002openalex-snapshot
Additional file 8 of Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.